AtriCure, Inc.
ATRCNASDAQHealthcare● Active
$26.97
$-0.13(-0.47%)
Market Cap$1.4B
P/E Ratio—
52W High$43.18
52W Low$25.36
AtriCure, Inc. (ATRC) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ATRC · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 5, 2026EPS Actual
$0.00
Est. -$0.07 · +103.1%
Revenue
$0.14B
Est. $0.14B · +1.1%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 5, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue🔥 7-Quarter EPS Beat Streak
ATRC reports quarterly as a NASDAQ-listed Medical - Instruments & Supplies company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.37
Rev. $0.36B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.37
Rev. Est.$0.36B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 4, 2026 | -$0.01 | — | — | — | $0.15B | — |
| ▲ Q2 FY2026 | May 5, 2026 | -$0.07 | $0.00 | +103.1% | $0.14B | $0.14B | +1.1% |
| ▲ Q1 FY2026 | Feb 17, 2026 | -$0.04 | $0.06 | +249.9% | $0.14B | $0.14B | +0.6% |
| ▲ Q4 FY2025 | Oct 29, 2025 | -$0.11 | -$0.01 | +90.9% | $0.13B | $0.14B | -4.4% |
| ▲ Q3 FY2025 | Jul 29, 2025 | -$0.15 | -$0.02 | +86.7% | $0.14B | $0.13B | +4.7% |
| ▲ Q2 FY2025 | Apr 29, 2025 | -$0.25 | -$0.14 | +44.0% | $0.12B | $0.13B | -5.3% |
| ▲ Q1 FY2025 | Feb 12, 2025 | -$0.23 | -$0.08 | +65.2% | $0.12B | $0.12B | +2.0% |
| ▲ Q4 FY2024 | Oct 29, 2024 | -$0.20 | -$0.17 | +15.0% | $0.12B | $0.12B | -3.3% |
Q3 FY2026
Aug 4, 2026
EPS Actual
—
EPS Est.
-$0.01
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 5, 2026Beat
EPS Actual
$0.00
EPS Est.
-$0.07
EPS Surpr.
+103.1%
Revenue
$0.14B
Q1 FY2026
Feb 17, 2026Beat
EPS Actual
$0.06
EPS Est.
-$0.04
EPS Surpr.
+249.9%
Revenue
$0.14B
Q4 FY2025
Oct 29, 2025Beat
EPS Actual
-$0.01
EPS Est.
-$0.11
EPS Surpr.
+90.9%
Revenue
$0.13B
Q3 FY2025
Jul 29, 2025Beat
EPS Actual
-$0.02
EPS Est.
-$0.15
EPS Surpr.
+86.7%
Revenue
$0.14B
Q2 FY2025
Apr 29, 2025Beat
EPS Actual
-$0.14
EPS Est.
-$0.25
EPS Surpr.
+44.0%
Revenue
$0.12B
Q1 FY2025
Feb 12, 2025Beat
EPS Actual
-$0.08
EPS Est.
-$0.23
EPS Surpr.
+65.2%
Revenue
$0.12B
Q4 FY2024
Oct 29, 2024Beat
EPS Actual
-$0.17
EPS Est.
-$0.20
EPS Surpr.
+15.0%
Revenue
$0.12B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.00 | $0.00 | $0.00 | 2 |
| Q3 FY2028 | $0.00 | $0.00 | $0.00 | 2 |
| Q2 FY2028 | $0.00 | $0.00 | $0.00 | 2 |
| Q1 FY2028 | $0.00 | $0.00 | $0.00 | 2 |
| Q4 FY2027 | $0.18 | $0.18 | $0.19 | 1 |
| Q3 FY2027 | $0.06 | $0.06 | $0.06 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.2B | $0.2B | $0.2B | 2 |
| Q3 FY2028 | $0.2B | $0.2B | $0.2B | 2 |
| Q2 FY2028 | $0.2B | $0.2B | $0.2B | 2 |
| Q1 FY2028 | $0.2B | $0.2B | $0.2B | 2 |
| Q4 FY2027 | $0.2B | $0.2B | $0.2B | 3 |
| Q3 FY2027 | $0.2B | $0.2B | $0.2B | 3 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 5, 2026 | +103.1% | $28.78 | $29.39 | +2.12% |
| ▲ Q1 FY2026 | Feb 17, 2026 | +249.9% | $32.65 | $32.97 | +0.98% |
| ▲ Q4 FY2025 | Oct 29, 2025 | +90.9% | $36.45 | $35.44 | -2.77% |
| ▲ Q3 FY2025 | Jul 29, 2025 | +86.7% | $33.22 | $31.73 | -4.49% |
| ▲ Q2 FY2025 | Apr 29, 2025 | +44.0% | $33.67 | $34.65 | +2.91% |
| ▲ Q1 FY2025 | Feb 12, 2025 | +65.2% | $41.51 | $42.36 | +2.05% |
| ▲ Q4 FY2024 | Oct 29, 2024 | +15.0% | $28.75 | $29.43 | +2.37% |
| ▼ Q3 FY2024 | Jul 30, 2024 | -13.3% | $21.96 | $22.00 | +0.18% |
Q2 FY2026+2.12%
Report Date
May 5, 2026
EPS Beat/Miss
+103.1%
Price Before
$28.78
Price After
$29.39
Q1 FY2026+0.98%
Report Date
Feb 17, 2026
EPS Beat/Miss
+249.9%
Price Before
$32.65
Price After
$32.97
Q4 FY2025-2.77%
Report Date
Oct 29, 2025
EPS Beat/Miss
+90.9%
Price Before
$36.45
Price After
$35.44
Q3 FY2025-4.49%
Report Date
Jul 29, 2025
EPS Beat/Miss
+86.7%
Price Before
$33.22
Price After
$31.73
Q2 FY2025+2.91%
Report Date
Apr 29, 2025
EPS Beat/Miss
+44.0%
Price Before
$33.67
Price After
$34.65
Q1 FY2025+2.05%
Report Date
Feb 12, 2025
EPS Beat/Miss
+65.2%
Price Before
$41.51
Price After
$42.36
Q4 FY2024+2.37%
Report Date
Oct 29, 2024
EPS Beat/Miss
+15.0%
Price Before
$28.75
Price After
$29.43
Q3 FY2024+0.18%
Report Date
Jul 30, 2024
EPS Beat/Miss
-13.3%
Price Before
$21.96
Price After
$22.00
Avg Beat Reaction+0.45%
Avg Miss Reaction+0.18%
Beat Rate7 / 8 quarters
Largest Move-4.49% (Q3 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ATRC ends December
AtriCure, Inc. (ATRC) most recently reported earnings on May 5, 2026 for Q2 FY2026, posting EPS of $0.00 — beating the analyst consensus of $-0.07 by +103.1%. ATRC has beaten EPS estimates for 7 consecutive quarters. The next ATRC earnings date is expected around September 1, 2026.
Each quarter, investors track ATRC earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ATRC revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ATRC's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ATRC earnings · 5 questionsAtriCure, Inc.'s next earnings report is expected around September 1, 2026. ATRC typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ATRC historically reports after market close (AMC).
ATRC earnings datewhen is ATRC earningsATRC next earnings datewhen does ATRC report earningsATRC earnings calendar
▸ Source: FMP · AtriCure, Inc. SEC filings · US GAAP · AtriCure, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026